
Opinion|Videos|July 10, 2024
EHA 2024 Insights: Impact of the IMROZ Study on Newly Diagnosed Multiple Myeloma
Joseph Mikhael, MD, discusses the latest trends and innovations regarding multiple myeloma management.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Please discuss the data presented at the European Hematology Association 2024 (EHA 2024) Hybrid Congress on the IMROZ study of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) vs VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM).
- Please provide your key takeaways from this study. How do the results of this study impact the treatment of patients with transplant-ineligible NDMM?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Advances in MASLD and MASH Care Highlight Progress and Persistent Gaps
2
Howard A. “Skip” Burris, III, MD: An Oncology Pioneer Reflects on Patients, Progress, and Purpose
3
Patients With Long-Term Conditions Prefer Remote Visits for Routine Care
4
Employer Premiums and Deductibles Consume Significant Portion of Income in 19 States
5















